BioSpace News Archive

Total revenue, including royalty and other revenue, was $210.6 million;

The Phase III CLL14 study compared Venclexta in combination with Gazyva to standard-of-care Gazyva plus chlorambucil

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum

Effort Urges Individuals At-Risk for Lung Cancer to Talk to Their Doctor About Life-Saving Screening

AgaMatrix and Arcadia Group announced today a strategic partnership leveraging AgaMatrix’s proprietary blood glucose monitoring (BGM) technology for the Choice line of diabetes products marketed by Arcadia.

Direct action to stop overburdening begins at midnight

Medical professional liability insurer adds 11th state as it continues its nationwide expansion

Prime Healthcare announced today that its hospitals have once again received best-in-the-nation recognition in key specialties from Healthgrades, the leading online resource for comprehensive and objective information about physicians and hospitals.

-CHOP and CEO Council for Growth Host Grand Opening, Signaling Philadelphia’s Emergence as Nation’s Biomedical Hub-